MRK - What's Going On With Merck Stock On Friday? | Benzinga
On Thursday, the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) unanimously voted to recommend Merck & Co Inc’s (NYSE:MRK) Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for adults 65 years of age and older. It is also commonly known as the pneumonia vaccine.
Specifically, the ACIP voted to recommend a single dose of Capvaxive for:
- Adults 65 years and older who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown.
- Adults 19-64 years of age with certain underlying medical conditions or other risk factors who have not previously received a pneumococcal conjugate vaccine or whose ...